Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma

Cancer

Volumn 83, Issue 9, 1998, Pages 1917-1922

  Cascinu, Stefano ^a   Graziano, Francesco ^a   Del Ferro, Elena ^a   Staccioli, Maria P ^a   Ligi, Marco ^a   Carnevali, Andrea ^a   Muretto, Pietro ^a   Catalano, Giuseppina ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Locally advanced gastric carcinoma; p53

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; STOMACH CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032211353     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981101)83:9<1917::AID-CNCR6>3.0.CO;2-1     Document Type: Article

References (30)

1. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen majors cancers in 1980. Int J Cancer 1988;41:184-7.
2. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ. Prognostic factors in gastric carcinoma. Cancer 1993;72:2089-97.
3. Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990;17(Suppl 2):61-70.
4. Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, et al. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1993;11: 22-8.
5. Rougier Ph, Lasser Ph, Ducreux M, Mahjoubi M, Bognel C, Elias D. Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 1994;5(Suppl 3):59-68.
6. Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996;14:1818-28.
7. Melcher AA, Mort D, Maughan TS. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastroesophageal cancer. Br J Cancer 1996; 74:1651-4.
8. Kelsen DP. Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 1996;23:379-89.
9. Leonard CJ, Canman CE, Kastan MB. The role of p53 in cell-cycle control and apoptosis: implications for cancer. In: DeVita V, Hellman S, Rosenberg SA. Important advances in oncology. Philadelphia: J. B. Lippincott, 1995:33-42.
10. Loewe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
11. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
12. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
13. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038-42.
14. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, et al. A comparative study of p53 gene mutations, protein accumulations, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-93.
15. Kim JH, Takahashi T, Chiba I, Park J, Birrer MJ, Roh JK, et al. Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst 1991;83:938-43.
16. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, et al. The prognostic significance of the accumulation of p53 tumor-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994;69:943-6.
17. Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76:720-6.
18. Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 1996;32A:215-20.
19. Yamaguchi A, Kurosaka Y, Fuscida S, Kanno M, Yonemura Y, Miwa K, et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992; 70:2778-84.
20. Glantz SA. Primer of biostatistics. 3rd edition. New York: McGraw Hill, 1992.
21. Nabeya Y, Loganzo F, Maslak P, Lai L, De Oliveira AR, Schwartz G, et al. The mutation of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensibility to chemotherapeutic agents. Int J Cancer 1994;64:1-10.
22. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996;122:360-5.
23. Nakata B, Chung YS, Ogawa Y, Inoue T, Ogawa M, Yamashita Y, et al. p53 and bcl-2 protein expression as predictors for the chemosensitivity in gastric cancer. Proc Am Assoc Cancer Res 1996;37:A1372.
24. Momand J, Zambetti G, Olson DC, George D, Levine AJ. The p53 oncogene product forms a complex with the p53 protein and inhibits p53-mRNA transactivation. Cell 1992;69:1237-45.
25. Bartek J, Bartkova J, Vojtesek B, Stakova Z, Lukas I, Rejthar A, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;5:1699-703.
26. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res 1991;51:3056-8.
27. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993;8:203-7.
28. Baas IO, Mulder JWR, Offerhaus JA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
29. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, et al. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993;67:589-93.
30. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, et al. Prognostic value of p53 nuclear overexpression in patients with massive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384-90.